RVO
HomeMarketplace

ServiceUpdated on 10 September 2025

Platform for de novo Peptide Discovery

Peter Timmerman

Head of Peptide Science at Biosynth B.V.

Lelystad, Netherlands

About

Biosynth developed a high-throughput screening platform for the de novo discovery of peptidic binders to any protein target of interest. The platform includes monocyclic peptides, Bibridged peptides, tricyclic peptides, as well as a newly developed model for biopanning using live cells (e.g. for membrane-embedded target proteins) and finally a high-throughput screening facility for affinity optimization of existing lead peptides.

Type

  • Development

Applies to

  • Innovative therapies - Precision medicine
  • Development stages and support fuctions - Pre-clinical research and development
  • Development stages and support fuctions - Contract research (CRO / CRMO)

Organisation

Biosynth B.V.

Company

Zuidersluisweg 2, 8243RC Lelystad, Switzerland

Similar opportunities